Immunomic Therapeutics Receives Positive Feedback From FDA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomic Therapeutics Receives Positive Feedback From FDA Following Pre-IND Discussions for Its Proprietary Peanut Allergy Vaccine

HERSHEY, Pa., and ROCKVILLE, Md., March 25, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it has concluded pre-IND discussions with the U.S. Food and Drug Administration regarding its proprietary ARA-LAMP-Vax vaccine currently under development for peanut allergies. The company received positive and helpful feedback, which it expects will be instrumental in designing its Phase 1 trials.

"Our meeting with the FDA proved illuminating and extremely helpful," said William Hearl, Ph.D., CEO of ITI. "Based on the feedback we received, we anticipate moving forward with our Phase 1 trials for our proprietary peanut allergy vaccine soon. We are grateful for the feedback, and look forward to continued collaboration with the Agency."

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:

  • ASP 4070 (Formerly known as JRC-LAMP-Vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
    • An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
  • ARA-LAMP-Vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
  • Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.

For more information about ITI and LAMP Technology, please visit www.immunomix.com .

Jules Abraham JQA Partners, Inc. (917) 885-7378 Sia Anagnostou Immunomic Therapeutics, Inc http://www.immunomix.com (717) 327-1822

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 53

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 161

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading

Top 5 Most Recently Viewed Articles

Leech Tishman Expands Healthcare Practice with Nelson Hardiman

Updated Category News Views 79

Leech Tishman Expands Its Healthcare Practice with Major Addition Leech Tishman is making a significant move in its growth strategy by merging with the respected healthcare firm, Nelson Hardiman. This collaboration is set to enhance Leech Tishman’s footprint in the healthcare sector, especially in the Southern California region, as they prepare to operate under the name...

Continue Reading
Schouw & Co. Announces Success in Share Buy-Back Program

Updated Category News Views 105

Schouw & Co. Share Buy-Back Program Overview Schouw & Co., a notable player in the business landscape, has embarked on an impactful share buy-back program that began recently. This strategic move allows the company to purchase shares worth up to DKK 50 million over a designated time frame, from January 2 to March 31. Such initiatives reflect the company's commitment to...

Continue Reading
Earnings Season Set to Shape Market Dynamics Amid Tariffs

Updated Category News Views 150

Understanding Market Sentiment During Earnings Season The upcoming earnings season presents an opportunity for Wall Street to shift its attention from external geopolitical factors to the internal dynamics of corporate performance. As companies prepare to unveil their second-quarter earnings reports, a closer look at how tariffs could influence consumer spending and,...

Continue Reading
Josh Ruben Joins the Board of PetVivo Holdings to Drive Growth

Updated Category News Views 316

Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) has announced the addition of Josh Ruben to its Board of Directors. This news comes from the company's efforts to further establish itself within the biomedical device sector aimed at improving the quality of life for companion animals. Transformational Leadership...

Continue Reading
Innovative Portable Solar and Wind Generator Concept Unveiled

Updated Category News Views 120

Your Sustainable Charging Solution We live in a time where sustainable energy solutions are becoming more paramount, and the invention of a portable solar and wind-powered generator meets that demand head-on. The concept builds on the idea that everyone deserves access to clean energy alternatives, especially for charging electronic devices. The Vision Behind the...

Continue Reading